- Home
- MHK vs TLX Comparison
MHK vs TLX Comparison
Compare MHK & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHK
- TLX
- Stock Information
- Founded
- MHK 1988
- TLX 2015
- Country
- MHK United States
- TLX Australia
- Employees
- MHK N/A
- TLX N/A
- Industry
- MHK Home Furnishings
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- MHK Consumer Discretionary
- TLX Health Care
- Exchange
- MHK Nasdaq
- TLX Nasdaq
- Market Cap
- MHK 7.2B
- TLX 6.0B
- IPO Year
- MHK 1992
- TLX N/A
- Fundamental
- Price
- MHK $114.21
- TLX $16.76
- Analyst Decision
- MHK Buy
- TLX Strong Buy
- Analyst Count
- MHK 13
- TLX 1
- Target Price
- MHK $147.69
- TLX $22.00
- AVG Volume (30 Days)
- MHK 747.7K
- TLX 31.6K
- Earning Date
- MHK 04-24-2025
- TLX 01-01-0001
- Dividend Yield
- MHK N/A
- TLX N/A
- EPS Growth
- MHK N/A
- TLX 798.14
- EPS
- MHK 8.14
- TLX 0.09
- Revenue
- MHK $10,836,900,000.00
- TLX $484,687,790.00
- Revenue This Year
- MHK $0.24
- TLX N/A
- Revenue Next Year
- MHK $3.32
- TLX N/A
- P/E Ratio
- MHK $14.03
- TLX $187.85
- Revenue Growth
- MHK N/A
- TLX 55.85
- 52 Week Low
- MHK $104.88
- TLX $14.01
- 52 Week High
- MHK $164.29
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- MHK 45.77
- TLX N/A
- Support Level
- MHK $110.80
- TLX N/A
- Resistance Level
- MHK $118.14
- TLX N/A
- Average True Range (ATR)
- MHK 3.12
- TLX 0.00
- MACD
- MHK 0.33
- TLX 0.00
- Stochastic Oscillator
- MHK 52.48
- TLX 0.00
About MHK Mohawk Industries Inc.
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.